Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 4, 2011, Pages 456-463

  Jianu, Constantin S ^a,b   Fossmark, Reidar ^a,b   Syversen, Unni ^a,b   Hauso, Øyvind ^a,b   Fykse, Vidar ^a   Waldum, Helge L ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Atrophic gastritis; chromogranin A; gastric carcinoids; gastrin; hypergastrinemia; somatostatin analogs

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; GASTRIN; INDIUM 111; LONG ACTING DRUG; OCTREOTIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; BLOOD ANALYSIS; CHRONIC GASTRITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE EXACERBATION; DISTANT METASTASIS; DRUG EFFECT; DYSPEPSIA; ENTEROCHROMAFFIN LIKE CELL; FEMALE; FLUSHING; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGIONAL METASTASIS; SIDE EFFECT; STOMACH BIOPSY; STOMACH CARCINOID; STOMACH CARCINOID TYPE 1; STOMACH GLAND; STOMACH SCINTISCANNING; STOMACH TUMOR; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; CARCINOID TUMOR; CHROMOGRANIN A; DISEASE PROGRESSION; ENTEROCHROMAFFIN-LIKE CELLS; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRINS; GASTRITIS, ATROPHIC; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 79952589102     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.539255     Document Type: Article

References (43)

1. Gough DB, Thompson GB, Crotty TB, Donohue JH, Kvols LK, Carney JA, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994;18:473-9; discussion 479-80.
2. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006.
3. Trudeau WL, McGuigan JE. Relations between serum gastrin levels and rates of gastric hydrochloric acid secretion. N Engl J Med 1971;284:408-12.
4. McGuigan JE, Trudeau WL. Serum gastrin concentrations in pernicious anemia. N Engl J Med 1970;282:358-61.
5. Ryberg B, Tielemans Y, Axelson J, Carlsson E, Hakanson R, Mattson H, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99:935-42.
6. Hakanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993;105:15-21.
7. Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut 1992;33:1303-6.
8. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985;88:638-48.
9. Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33:88-92.
10. Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston city hospital. N Engl J Med 1955;252:1103-10.
11. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134-49.
12. Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin a and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994;26:201-6.
13. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin a as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-8.
14. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin a and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-a gastritis. Scand J Gastroenterol 1997;32:198-202.
15. Hakanson R, Ding XQ, Norlen P, Chen D. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 1995;108:1445-52.
16. Waldum HL, Syversen U. Chromogranin a (cga) and the enterochromaffin-like (ecl) cell. Adv Exp Med Biol 2000; 482:361-7.
17. Soga J. Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature. Surg Today 1997;27:892-901.
18. Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion 1995;56:455-62.
19. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. Ecl cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116: 532-42.
20. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242:64-73.
21. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153-72.
22. Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, Dockray GJ, Thompson DG. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998;114:817-22.
23. Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989;68: 796-800.
24. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group. J Clin Oncol 2009;27(28):4656-63.
25. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ecl cell carcinoids with octreotide lar. Scand J Gastroenterol 2004;39:621-8.
26. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008;159:475-82.
27. Jianu CS, Fossmark R, Syversen U, Hauso O, Waldum HL. A meal test improves the specificity of chromogranin a as a marker of neuroendocrine neoplasia. Tumour Biol 2010;31 (5):373-80.
28. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, et al. Gastric endocrine tumors type i: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008;15:337-42.
29. Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol 2005;40:1269-74.
30. Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol 2009;25:548-54.
31. Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/ or pernicious anemia. Apmis 2002;110:132-9.
32. Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125i-gastrin, using iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985;20:569-76.
33. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
34. Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol 1999;31(Suppl 2):S94-7.
35. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20: 168-72.
36. Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut 1993;34:28-32.
37. Qvigstad G, Falkmer S, Westre B, Waldum HL. Clinical and histopathological tumour progression in ecl cell carcinoids ("Eclomas" ). Apmis 1999;107:1085-92.
38. Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2010;45:389-94.
39. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
40. Borch K. Atrophic gastritis and gastric carcinoid tumours. Ann Med 1989;21:291-7.
41. Sjoblom SM, Sipponen P, Miettinen M, Karonen SL, Jrvinen HJ. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy 1988;20: 52-6.
42. Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK. Enterochromaffin-like tumour cells in the diffuse but not the intestinal type of gastric carcinomas. Scand J Gastroenterol Suppl 1991;180:165-9.
43. Waldum HL, Burhol PG. The effect of somatostatin on serum group i pepsinogens (pg i), serum gastrin, and gastric h+ and pepsin secretion in man. Scand J Gastroenterol 1980; 15:425-31.